FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993501129> ?p ?o ?g. }

• W2993501129 abstract "Nrf2, a key orchestrator of cell defense mechanisms against oxidative stress and xenobiotic insults, has been linked to chemotherapy resistance and recurrence in many human cancers. Through the establishment of an in vitro model of chemoresistance, we investigated the role of Nrf2 in sustaining resistance to chemotherapy in medulloblastoma (MB), a highly aggressive pediatric brain tumor intrinsically characterized by fast growth, high invasiveness and resistance to treatments. MB DAOY cells were weekly exposed to a cocktail of drugs commonly used in MB treatment, vincristine, etoposide, cisplatin and cyclophosphamide (VECC) inducing the emergence of a resistant phenotype. After 5 cycles of VECC treatment we obtained a culture of cells resistant to subsequent chemotherapy treatments. We observed increased Nrf2 levels and activity in therapy-exposed cells already from the first received dose of VECC. Nrf2 levels remained high throughout all the rest of chemotherapy cycles and interestingly, its transcriptional activity spiked up when resistance to chemotherapy emerged, as demonstrated by the increase of antioxidant response element (ARE)-driven luciferase activity and the expression of target genes. The knock down of Nrf2 in resistant cells, by the use of specific siRNA, was able to restore chemosensitivity, suggesting a role of Nrf2 signaling pathway in the onset of chemotherapy resistance in MB cells. Resistant cells showed a higher ROS (reactive oxygen species) scavenging capacity after stimulation with hydrogen peroxide. Nrf2 silencing partially reverts the ability of resistant cells to manage oxidative stress, supporting the hypothesis of Nrf2 involvement in the ROS scavenging potential of VECC resistant MB cells. In addition to directly regulate ROS-scavenging enzymes, Nrf2 has been described to control cell metabolism that maintain redox homeostasis in cancer stem cells. Among the Nrf2 target genes upregulated in DAOY resistant cells we found the upregulation of PFKFB-3, G6PD and TKT. The increased expression of this enzymes suggests a metabolic reprogramming in resistant cells. Our data support the involvement of Nrf2 pathway in MB response to VECC treatment and show that the upregulation of this detoxifying system sustains MB resistance to chemotherapy. Citation Format: Fatlum Rruga, Elena Mariotto, Luca Persano, Elena Rampazzo, Alessandra Luchini, Lance A Liotta, Giampietro Viola, Roberta Bortolozzi. Role of the NRF2 signaling pathway in sustaining chemoresistance in medulloblastoma [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A066. doi:10.1158/1535-7163.TARG-19-A066" @default.
• W2993501129 created "2019-12-13" @default.
• W2993501129 creator A5001497347 @default.
• W2993501129 creator A5003987144 @default.
• W2993501129 creator A5041904608 @default.
• W2993501129 creator A5046895349 @default.
• W2993501129 creator A5051460984 @default.
• W2993501129 creator A5052223562 @default.
• W2993501129 creator A5063620408 @default.
• W2993501129 creator A5086886026 @default.
• W2993501129 date "2019-12-01" @default.
• W2993501129 modified "2023-10-14" @default.
• W2993501129 title "Abstract A066: Role of the NRF2 signaling pathway in sustaining chemoresistance in medulloblastoma" @default.
• W2993501129 doi "https://doi.org/10.1158/1535-7163.targ-19-a066" @default.
• W2993501129 hasPublicationYear "2019" @default.
• W2993501129 type Work @default.
• W2993501129 sameAs 2993501129 @default.
• W2993501129 citedByCount "0" @default.
• W2993501129 crossrefType "proceedings-article" @default.
• W2993501129 hasAuthorship W2993501129A5001497347 @default.
• W2993501129 hasAuthorship W2993501129A5003987144 @default.
• W2993501129 hasAuthorship W2993501129A5041904608 @default.
• W2993501129 hasAuthorship W2993501129A5046895349 @default.
• W2993501129 hasAuthorship W2993501129A5051460984 @default.
• W2993501129 hasAuthorship W2993501129A5052223562 @default.
• W2993501129 hasAuthorship W2993501129A5063620408 @default.
• W2993501129 hasAuthorship W2993501129A5086886026 @default.
• W2993501129 hasConcept C104317684 @default.
• W2993501129 hasConcept C119056186 @default.
• W2993501129 hasConcept C2776151105 @default.
• W2993501129 hasConcept C2776694085 @default.
• W2993501129 hasConcept C2776755627 @default.
• W2993501129 hasConcept C2778119113 @default.
• W2993501129 hasConcept C2778239845 @default.
• W2993501129 hasConcept C2779429289 @default.
• W2993501129 hasConcept C48349386 @default.
• W2993501129 hasConcept C502942594 @default.
• W2993501129 hasConcept C54355233 @default.
• W2993501129 hasConcept C55493867 @default.
• W2993501129 hasConcept C81885089 @default.
• W2993501129 hasConcept C86803240 @default.
• W2993501129 hasConcept C95444343 @default.
• W2993501129 hasConcept C98274493 @default.
• W2993501129 hasConceptScore W2993501129C104317684 @default.
• W2993501129 hasConceptScore W2993501129C119056186 @default.
• W2993501129 hasConceptScore W2993501129C2776151105 @default.
• W2993501129 hasConceptScore W2993501129C2776694085 @default.
• W2993501129 hasConceptScore W2993501129C2776755627 @default.
• W2993501129 hasConceptScore W2993501129C2778119113 @default.
• W2993501129 hasConceptScore W2993501129C2778239845 @default.
• W2993501129 hasConceptScore W2993501129C2779429289 @default.
• W2993501129 hasConceptScore W2993501129C48349386 @default.
• W2993501129 hasConceptScore W2993501129C502942594 @default.
• W2993501129 hasConceptScore W2993501129C54355233 @default.
• W2993501129 hasConceptScore W2993501129C55493867 @default.
• W2993501129 hasConceptScore W2993501129C81885089 @default.
• W2993501129 hasConceptScore W2993501129C86803240 @default.
• W2993501129 hasConceptScore W2993501129C95444343 @default.
• W2993501129 hasConceptScore W2993501129C98274493 @default.
• W2993501129 hasLocation W29935011291 @default.
• W2993501129 hasOpenAccess W2993501129 @default.
• W2993501129 hasPrimaryLocation W29935011291 @default.
• W2993501129 hasRelatedWork W11467293 @default.
• W2993501129 hasRelatedWork W12443642 @default.
• W2993501129 hasRelatedWork W13371306 @default.
• W2993501129 hasRelatedWork W1473125 @default.
• W2993501129 hasRelatedWork W22121506 @default.
• W2993501129 hasRelatedWork W24553618 @default.
• W2993501129 hasRelatedWork W28555664 @default.
• W2993501129 hasRelatedWork W35311423 @default.
• W2993501129 hasRelatedWork W3890397 @default.
• W2993501129 hasRelatedWork W29442920 @default.
• W2993501129 isParatext "false" @default.
• W2993501129 isRetracted "false" @default.
• W2993501129 magId "2993501129" @default.
• W2993501129 workType "article" @default.